Reportedly, Pfizer (PFE) has entered a $1.95 billion deal to provide 100 million doses of a COVID-19 vaccine to the U.S. government, with an additional right to purchase more 500 million doses. The company said that the Americans will be treated with the vaccine for free. The vaccine is in development with BioNTech and expects to start the next trial later this month. Pfizer is looking forward to gaining regulatory review and acceptance as early as October. The company is looking forward to manufacturing up to 100 million doses by the end of 2020 and more than 1.3 million doses by the end of 2021.
The move is the latest effort by the U.S government to work and look for treatments and vaccines for the COVID-19 pandemic, which has affected more than 4 million U.S people and has hampered the economy.
“Now those would, of course, have to be safe and effective” and be approved by the Food and Drug Administration, U.S. Department of Health and Human Services Secretary Alex Azar stated on Fox News.
Pfizer (PFE) is a leading global provider of anti-infective medicines, offering patients access to a diverse portfolio of more than 80 products. To learn more about Pfizer (PFE) and to track its progress please visit the Vista Partners Pfizer Coverage Page.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.